Kymera Therapeutics, Inc. is in a growth phase on multiple fronts. The company is building out a clinical stage pipeline of oral targeted protein degraders for potentially large immunology indications. In January it closed a public offering that grossed $316.2m. The company’s stock price is up 37% from the start of the year, and Kymera has recently moved into a new, larger corporate headquarters in Watertown, Mass.
Kymera Puts Emphasis On Immunology In New Growth Phase
CEO Nello Mainolfi talked to Scrip about Kymera’s pipeline expansion, which will prioritize oral targeted protein degraders in immunology, including two new assets moving into the clinic.
